pBI-11 (1 dose)

Phase 2Biologic

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

pBI-11 (1 dose) is one of 2 biologic programs targeting HPV Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV InfectionRecruiting

HPV InfectionPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in HPV Infection

#DrugCompanyPhaseTrials

Gardasil HPV Vaccine

LLondon School of Hygiene and Tropical Medicine

Phase 3

1 2

pBI-11 (1 dose)

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

HPV Infection

NCT06210854

Clinical

Trials by Indication[1]

HPV Infection1 trial

Double-Blind Randomized Phase II Clinical Trial Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ <CIN2

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06210854·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pBI-11 (1 dose). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pBI-11 (1 dose) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pBI-11 (1 dose). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

pBI-11 (1 dose)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

HPV Infection1 trial

References

Drug Info

Quick Facts

Related News